Combination of lipitor and celebrex inhibits prostate cancer VCaP cells in vitro and in vivo

Huarong Huang, Xiao Xing Cui, Shaohua Chen, Susan Goodin, Yue Liu, Yan He, Dongli Li, Hong Wang, Jeremiah Van Doren, Robert S. Dipaola, Allan H. Conney, Xi Zheng

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


Background/Aim: Lipitor is a cholesterollowering drug and Celebrex is a Cyclooxygenase-2 inhibitor. We investigated the effects of Lipitor and Celebrex on human prostate cancer VCaP cells cultured in vitro and grown as orthotopic xenograft tumors in SCID mice. Materials and Methods: Apoptosis was measured by morphological assessment and caspase-3 assay. Nuclear factor-kappa B (NF-κB) activation was determined by luciferase reporter assay. B-cell lymphoma-2 (Bcl2) was measured by western blotting and immunohistochemistry. Orthotopic prostate tumors were monitored by the IVIS imaging system. Results: the combination of Lipitor and Celebrex had stronger effects on the growth and apoptosis of VCaP cells than did either drug alone. The combination more potently inhibited activation of NFκB and expression of Bcl2 than either drug alone. The growth of orthotopic VCaP prostate tumors was strongly inhibited by treatment with the drug combination. Conclusion: Administration of Lipitor and Celebrex in combination may be an effective strategy for inhibiting the growth of prostate cancer.

Original languageEnglish
Pages (from-to)3357-3363
Number of pages7
JournalAnticancer Research
Issue number7
StatePublished - Jul 1 2014


  • NFκB
  • NSAIDs
  • Orthotopic
  • Prostate cancer
  • Statin

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Combination of lipitor and celebrex inhibits prostate cancer VCaP cells in vitro and in vivo'. Together they form a unique fingerprint.

Cite this